Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625385 · ClinicalTrials.gov registry record · NA
A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing
A NA study of Wound, sponsored by Solventum US.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 3
- Study locations
NCT06625385: Recruiting NA study of Wound, sponsored by Solventum US.
NCT06625385 is a NA study of Wound that is actively recruiting participants, run by Solventum US. The registered enrollment target is 90 participants, below the 414-participant average among 8 other Wound trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06625385, a NA study of Wound, is actively recruiting participants, sponsored by Solventum US.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this clinical study is to obtain post-market safety and efficacy data when the V.A.C.® Peel and Place dressing is used in conjunction with 3M™ V.A.C.® Therapy.
Primary Outcome
The incidence of adverse device effects (ADEs)
Conditions Studied
Interventions
- DEVICE 3M™ V.A.C.® Peel and Place Dressing
Study Locations (3)
Indiana
- IU Health Methodist Hospital - Indianapolis
Missouri
- Washington University - Barnes Jewish Hospital - St Louis
Pennsylvania
- St. Luke's University Hospital - Bethlehem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-01-20 |
| Est. Completion | 2027-05 |
| Phase | NA |
What NCT06625385 shows while recruiting
NCT06625385 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 414-participant average among 8 other Wound trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Wound appearing as the primary indexed condition, and to 1 intervention - of which 3M™ V.A.C.® Peel and Place Dressing is the first listed.
NCT06625385 reports a single indexed study location in Indiana, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06625385 about?
NCT06625385 is a clinical study titled "A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing". The purpose of this clinical study is to obtain post-market safety and efficacy data when the V.A.C.® Peel and Place dressing is used in conjunction with 3M™ V.A.C.® Therapy.
What is the current status of trial NCT06625385?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2025-01-20. Estimated completion is 2027-05.
What conditions does trial NCT06625385 study?
This clinical trial studies the following conditions: Wound.
What interventions are being tested in trial NCT06625385?
The interventions under investigation include: 3M™ V.A.C.® Peel and Place Dressing (DEVICE).
Who is sponsoring clinical trial NCT06625385?
This trial is sponsored by Solventum US, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625385 being conducted?
This trial has 3 study locations across Indiana, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wound
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06625385's enrollment target sits among peer trials
90 5th of 8 higher than 4 of 8 other Wound trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wound trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Miro3D Randomized Controlled Trial (RCT)
RECRUITING · NA
-
Diabetic Foot Ulcer (DFU) Rapid Pathogen Identification
COMPLETED · NA
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
Novel Strategies for Reducing Burn Scar Itch
RECRUITING · Phase 3
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Wound Healing Endpoint and Recurrence
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI